MedTrace Logo

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

NCT05159440 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-10-22

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer

Conditions

  • Advanced Solid Tumor
  • Gastric Cancer
  • Pancreas Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

TORL-2-307-MAB

monoclonal antibody

Sponsors & Collaborators

  • Translational Research in Oncology

    collaborator OTHER

  • TORL Biotherapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Stephen Letrent, PharmD, PhD · TORL Biotherapeutics, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2024-12-15
Completion
2025-12-15
FDA Drug
Yes

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159440 on ClinicalTrials.gov